drugset
drugset / Trial / NCT05936359

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT05936359 ↗

Phase 1 Recruiting 225 enrolled Incyte Corporation
Non-randomizedSequentialOpen-labelTreatment

Summary

This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.

Timeline

Start
2023-09-25
Primary completion
2028-02-29
Completion
2028-02-29

Drugs

EvaluationDrugModalityDoseRoute
Subject INCA033989 Unknown — —
Background Ruxolitinib Small molecule — —

Indications

myeloproliferative neoplasm